Revising the role of the androgen receptor in breast cancer

Journal of Molecular Endocrinology

Volumn 52, Issue 3, 2014, Pages

  Fioretti, F M ^a   Sita Lumsden, A ^a   Bevan, C L ^a   Brooke, G N ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Androgen receptors; Breast cancer; Oestrogen receptor; Steroid

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ABIRATERONE ACETATE; ANDROGEN; ANDROSTANE DERIVATIVE; ANILIDE; ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; NITRILE; STEROID 17ALPHA MONOOXYGENASE; TAMOXIFEN; TOLUENESULFONIC ACID DERIVATIVE;

ANDROGEN SYNTHESIS; ANTIPROLIFERATIVE ACTIVITY; BASEMENT MEMBRANE; BREAST CANCER; BREAST DEVELOPMENT; CANCER PATIENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DNA BINDING; DNA RESPONSIVE ELEMENT; ESTROGEN RESPONSIVE ELEMENT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GONADOTROPIN RELEASE; HORMONE RESPONSIVE ELEMENT; HUMAN; HYPOPHYSIS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOHISTOCHEMISTRY; INVERTED REPEAT; LIGAND BINDING; LNCAP CELL LINE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE FEEDBACK; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; FEMALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

ABIRATERONE ACETATE; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTADIENES; ANILIDES; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NITRILES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TAMOXIFEN; TOSYL COMPOUNDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84901441387     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0030     Document Type: Review

References (85)

1. Attard G., Belldegrun AS & de Bono JS 2005 Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International 96 1241-1246. (doi:10.1111/j.1464-410X.2005.05821.x)
2. Beato M. 1989 Gene regulation by steroid hormones. Cell 56 335-344. (doi:10.1016/0092-8674(89)90237-7)
3. Birrell S. N, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ & Tilley W. D 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467. (doi:10.1016/0960-0760(95)00005-K)
4. BjörnströmL & Sjöberg M 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology 19 833-842. (doi:10.1210/me.2004-0486)
5. Brooke G. N & Bevan CL 2009 The role of androgen receptor mutations in prostate cancer progression. Current Genomics 10 18-25. (doi:10.2174/ 138920209787581307)
6. Burger H. G 2002 Androgen production in women. Fertility and Sterility 77 (Suppl 4) S3-S5. (doi:10.1016/S0015-0282(02)02985-0)
7. Cardoso F., Bischoff J, Brain E, Zotanoá G, Lück HJ, Tjan-Heijnen VC, Tanner M. & Aapro M 2013 A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treatment Reviews 39 457-465. (doi:10.1016/j.ctrv.2012.06.011)
8. Carroll J. S, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton E. K, Fertuck KC, Hall GF et al. 2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289-1297. (doi:10.1038/ng1901)
9. Castellano I., Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A., Donadio M, Bussolati G, Coates AS et al. 2010 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment 124 607-617. (doi:10.1007/s10549-010-0761-y)
10. Chang Y. F, Hung SH, Lee YJ, Chen RC, Su LC, Lai CS & Chou C 2011 Discrimination of breast cancer by measuring prostate-specific antigen levels in women's serum. Analytical Chemistry 83 5324-5328. (doi:10.1021/ac200754x)
11. Chia K. M, Liu J, Francis GD & Naderi A 2011 A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13 154-166. (doi:10.1593/neo.101324)
12. Claessens F., Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G & Rombauts W 2001 Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. Journal of Steroid Biochemistry and Molecular Biology 76 23-30. (doi:10.1016/S0960-0760(00)00154-0)
13. Cops E. J, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM & Tilley W. D 2008 Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology 110 236-243. (doi:10.1016/j.jsbmb.2007.10.014)
14. CRUK 2014 Key Facts: Breast Cancer. Last Accessed 1st May 2014. http://publications.cancerresearchuk.org/downloads/Product/ CS_KF_ BREAST.pdf
15. Dimitrakakis C., Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D & Bondy C. 2003 A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10 292-298. (doi:10.1097/01. GME.0000055522.67459.89)
16. Doane A. S, Danso M, Lal P, Donaton M, Zhang L, Hudis C & Gerald WL 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 3994-4008. (doi:10.1038/sj.onc.1209415)
17. Falkenstein E., Tillmann HC, Christ M, Feuring M & Wehling M 2000 Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacological Reviews 52 513-556.
18. Farmer P., Bonnefoi H, BecetteV, Tubiana-Hulin M, Fumoleau P, LarsimontD, Macgrogan G., Bergh J, Cameron D, Goldstein D et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 4660-4671. (doi:10.1038/sj.onc.1208561)
19. Garay J. P & Park BH 2012 Androgen receptor as a targeted therapy for breast cancer. American Journal of Cancer Research 2 434-445.
20. Glass C. K 1994 Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocrine Reviews 15 391-407. (doi:10.1210/edrv-15-3-391)
21. Cip1/Waf1. Journal of Molecular Endocrinology 32 793-810. (doi:10.1677/jme.0.0320793)
22. Gucalp A., Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H., Nabell L, Forero A et al. 2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clinical Cancer Research 19 5505-5512. (doi:10.1158/1078-0432.CCR-12-3327)
23. Hall R. E, Aspinall JO, Horsfall DJ, Birrell SN, Bentel JM, Sutherland RL & Tilley W. D 1996 Expression of the androgen receptor and an androgenresponsive protein, apolipoprotein D, in human breast cancer. British Journal of Cancer 74 1175-1180. (doi:10.1038/bjc.1996.513)
24. He J., Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X & Qin T 2012 Prognostic value of androgen receptor expression in operable triplenegative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology 29 406-410. (doi:10.1007/s12032-011-9832-0)
25. Héquet D., Bricou A, Delpech Y & Barranger E 2011 Surgical management modifications following systematic additional shaving of cavity margins in breast-conservation treatment. Annals of Surgical Oncology 18 114-118. (doi:10.1245/s10434-010-1211-0)
26. Hockings J. K, Degner SC, Morgan SS, Kemp MQ & Romagnolo DF 2008 Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. Breast Cancer Research 10 R29. (doi:10.1186/bcr1987)
27. Hu R., Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson S. E, Colditz GA & Tamimi RM 2011 Androgen receptor expression and breast cancer survival in postmenopausal women. Clinical Cancer Research 17 1867-1874. (doi:10.1158/1078-0432.CCR-10-2021)
28. Jeffy B. D, Hockings JK, Kemp MQ, Morgan SS, Hager JA, Beliakoff J, Whitesell L. J, Bowden GT & Romagnolo DF 2005 An estrogen receptor-α/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 7 873-882. (doi:10.1593/neo.05256)
29. Jordan V. C 2007 SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute 99 350-356. (doi:10.1093/jnci/djk062)
30. Karrer-Voegeli S., Rey F, Reymond MJ, Meuwly JY, Gaillard RC & Gomez F 2009 Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine 88 32-45. (doi:10.1097/md.0b013e3181946a2c)
31. Lanzino M., De Amicis F, McPhaul MJ, Marsico S, Panno ML & Andò S 2005 Endogenous coactivator ARA70 interacts with estrogen receptor α (ERα) and modulates the functional ERα/androgen receptor interplay in MCF-7 cells. Journal of Biological Chemistry 280 20421-20430. (doi:10.1074/jbc.M413576200)
32. Lehmann B. D, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol J. A 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/ JCI45014)
33. Le Romancer M., Poulard C, Cohen P, Sentis S, Renoir JM & Corbo L 2011 Cracking the estrogen receptor's posttranslational code in breast tumors. Endocrine Reviews 32 597-622. (doi:10.1210/er.2010-0016)
34. Li S., Han B, Liu G, Ouellet J, Labrie F & Pelletier G 2010 Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. Journal of Histochemistry and Cytochemistry 58 509-515. (doi:10.1369/jhc.2009.954644)
35. Lin H. Y, SunM, Lin C, Tang HY, London D, Shih A, Davis FB& Davis PJ 2009 Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-α-positive and-negative breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 113 182-188. (doi:10.1016/j.jsbmb.2008.12.010)
36. Loibl S., Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B., du Bois A, Fissler-Eckhoff A, Gerber B et al. 2011 Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 130 477-487. (doi:10.1007/ s10549-011-1715-8)
37. Luo X., Shi YX, Li ZM& Jiang WQ 2010 Expression and clinical significance of androgen receptor in triple negative breast cancer. Chinese Journal of Cancer 29 585-590. (doi:10.5732/cjc.009.10673)
38. Macedo L. F, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y & Brodie A 2006 Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Research 66 7775-7782. (doi:10.1158/0008-5472.CAN-05-3984)
39. Macias H. & Hinck L 2012 Mammary gland development. Wiley Interdisciplinary Reviews. Developmental Biology 1 533-557. (doi:10.1002/ wdev.35)
40. Maggiolini M., Donzé O, Jeannin E, Andò S & Picard D 1999 Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Research 59 4864-4869.
41. Mangelsdorf D. J, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B., Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839. (doi:10. 1016/0092-8674(95)90199-X)
42. Massie C. E, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H., Madhu B, Sharma N et al. 2011 The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal 30 2719-2733. (doi:10.1038/emboj.2011.158)
43. McGhan L. J, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R., Castle EP, Gray RJ, Wasif N, Goetz MP et al. 2014 Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Annals of Surgical Oncology 21 361-367. (doi:10.1245/s10434-013-3260-7)
44. Micello D., Marando A, Sahnane N, Riva C, Capella C & Sessa F 2010 Androgen receptor is frequently expressed in HER2-positive, ER/PRnegative breast cancers. Virchows Archiv 457 467-476. (doi:10.1007/ s00428-010-0964-y)
45. Mohajeri A., Zarghami N, Pourhasan Moghadam M, Alani B, Montazeri V, Baiat A. & Fekhrjou A 2011 Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors. Oncology Research 19 375-380. (doi:10. 3727/096504011X13123323849636)
46. Mrklić I., Pogorelić Z, Capkun V & Tomić S 2013 Expression of androgen receptors in triple negative breast carcinomas. Acta Histochemica 115 344-348. (doi:10.1016/j.acthis.2012.09.006)
47. Naderi A. & Hughes-Davies L 2008 A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10 542-548. (doi:10.1593/neo.08274)
48. Niemeier L. A, Dabbs DJ, Beriwal S, Striebel JM& Bhargava R 2010 Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern Pathology 23 205-212. (doi:10.1038/modpathol. 2009.159)
49. Nuti M., Bellati F, ViscontiV, NapoletanoC, Domenici L, Caccetta J, Zizzari IG, Ruscito I., Rahimi H, Benedetti-Panici P et al. 2011 Immune effects of trastuzumab. Journal of Cancer 2 317-323. (doi:10.7150/jca.2.317)
50. Olefsky J. M 2001 Nuclear receptor minireview series. Journal of Biological Chemistry 276 36863-36864. (doi:10.1074/jbc.R100047200)
51. ONS 2013 Cancer Registration Statistics, England, 2011. Last Accessed 1st May 2014. http://www.ons.gov.uk/ons/dcp171778_315795.pdf.
52. Ortmann J., Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T. 2002 Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecological Endocrinology 16 113-120. (doi:10.1080/713603030)
53. Page D. L, Dupont WD, Rogers LW & Rados MS 1985 Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55 2698-2708. (doi:10.1002/1097-0142(19850601)55:11!2698::AIDCNCR2820551127O3.0. CO;2-A)
54. Panet-Raymond V., Gottlieb B, Beitel LK, Pinsky L & Trifiro MA 2000 Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Molecular and Cellular Endocrinology 167 139-150. (doi:10.1016/S0303-7207(00)00279-3)
55. Papadatos-Pastos D., Dedes KJ, de Bono JS & Kaye SB 2011 Revisiting the role of antiandrogen strategies in ovarian cancer. Oncologist 16 1413-1421. (doi:10.1634/theoncologist.2011-0164)
56. Park S., Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW & Lee KS 2010 Expression of androgen receptors in primary breast cancer. Annals of Oncology 21 488-492. (doi:10.1093/annonc/mdp510)
57. Park S., Koo JS, Kim MS, Park HS, Lee JS, Kim SI, Park BW & Lee KS 2011 Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Annals of Oncology 22 1755-1762. (doi:10.1093/annonc/mdq678)
58. Parkin D. M, Boyd L & Walker LC 2011 The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. British Journal of Cancer 105 (Suppl 2) S77-S81. (doi:10.1038/bjc.2011.489)
59. Perez E. A, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S., Mamounas EP, Kaufman PA & Wolmark N 2011 Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology 29 3366-3373. (doi:10.1200/JCO.2011.35.0868)
60. Perou C. M, Sørlie T, Eisen MB, van de RijnM, Jeffrey SS, Rees CA, Pollack JR, Ross D. T, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
61. Peters A. A, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris J. M, Jindal S, Segara D, Jia L, Moore NL et al. 2009 Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Research 69 6131-6140. (doi:10.1158/0008-5472.CAN-09-0452)
62. Peters A. A, Ingman WV, Tilley WD & Butler LM 2011 Differential effects of exogenous androgen and an androgen receptor antagonist in the peri-and postpubertal murine mammary gland. Endocrinology 152 3728-3737. (doi:10.1210/en.2011-1133)
63. Pratt W. B & Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews 18 306-360. (doi:10.1210/edrv.18.3.0303)
64. Rakha E. A, El-Sayed ME, Green AR, Lee AH, Robertson JF & Ellis IO 2007 Prognostic markers in triple-negative breast cancer. Cancer 109 25-32. (doi:10.1002/cncr.22381)
65. Risbridger G. P, Davis ID, Birrell SN & Tilley WD 2010 Breast and prostate cancer: more similar than different. Nature Reviews. Cancer 10 205-212. (doi:10.1038/nrc2795)
66. Robinson J. L, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG & Carroll J. S 2011 Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal 30 3019-3027. (doi:10.1038/emboj.2011.216)
67. Robinson-Rechavi M., Escriva Garcia H & Laudet V 2003 The nuclear receptor superfamily. Journal of Cell Science 116 585-586. (doi:10.1242/ jcs.00247)
68. Ross J. S, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM & Hortobagyi GN 2009 The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14 320-368. (doi:10.1634/theoncologist.2008-0230)
69. Schippinger W., Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H. & Moinfar F 2006 Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Archiv 449 24-30. (doi:10.1007/s00428-006-0213-6)
70. Schnitt S. J, Silen W, Sadowsky NL, Connolly JL & Harris JR 1988 Ductal carcinoma in situ (intraductal carcinoma) of the breast. New England Journal of Medicine 318 898-903. (doi:10.1056/ NEJM198804073181406)
71. Søiland H., Kørner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, Baak J. P & Søreide JA 2008 Prognostic relevance of androgen receptor detection in operable breast cancer. Journal of Surgical Oncology 98 551-558. (doi:10.1002/jso.21156)
72. Søreide J. A, Lea OA, Varhaug JE, Skarstein A & Kvinnsland S 1992 Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. European Journal of Surgical Oncology 18 112-118.
73. Sørlie T., PerouCM, Tibshirani R, AasT, Geisler S, JohnsenH, HastieT, EisenMB, van de Rijn M., Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
74. Sutton L. M, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B & Peng Y 2012 Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triplenegative breast carcinoma. American Journal of Clinical Pathology 138 511-516. (doi:10.1309/AJCP8AVF8FDPTZLH)
75. Tang D., Xu S, Zhang Q & Zhao W 2012 The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Medical Oncology 29 526-533. (doi:10.1007/s12032-011-9948-2)
76. Tran C., Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones P. M, Yoo D, Kwon A et al. 2009 Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
77. Tsang J. Y, Ni YB, Chan SK, Shao MM, Law BK, Tan PH & Tse GM 2014 Androgen receptor expression shows distinctive significance in er positive and negative breast cancers. Annals of Surgical Oncology (In press). (doi:10.1245/s10434-014-3629-2)
78. Turner N. C & Reis-Filho JS 2013 Tackling the diversity of triple-negative breast cancer. Clinical Cancer Research 19 6380-6388. (doi:10.1158/ 1078-0432.CCR-13-0915)
79. Turner N., Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer F. C, van Kouwenhove M, Kreike B, Mackay A et al. 2010 Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29 2013-2023. (doi:10.1038/onc.2009.489)
80. Unni E., Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA & Marcelli M 2004 Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Research 64 7156-7168. (doi:10.1158/0008-5472.CAN-04-1121)
81. Wirapati P., Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C., Ignatiadis M, Sengstag T, Schütz F et al. 2008 Metaanalysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research 10 R65. (doi:10.1186/bcr2124)
82. Wong C. W, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activitycrosstalk with Src/Erk phosphorylation cascade. PNAS 99 14783-14788. (doi:10.1073/pnas.192569699)
83. Yeh S., Hu YC, Wang PH, Xie C, Xu Q, Tsai MY, Dong Z, Wang RS, Lee TH & Chang C. 2003 Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. Journal of Experimental Medicine 198 1899-1908. (doi:10.1084/jem.20031233)
84. Yu H., Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R., Ponzone R & Sismondi P 1995 Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 55 2104-2110.
85. Zhou J., Ng S, Adesanya-Famuiya O, Anderson K & Bondy CA 2000 Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB Journal 14 1725-1730. (doi:10.1096/fj.99-0863com)